ImmuCell Company Insiders
| ICCC Stock | USD 6.15 0.04 0.65% |
ImmuCell employs about 77 people. The company is managed by 8 executives with a total tenure of roughly 44 years, averaging almost 5.0 years of service per executive, having 9.63 employees per reported executive. Evaluation of ImmuCell's management performance can provide insight into the firm performance.
| Michael Brigham CEO CEO and President CFO, Treasurer, Secretary and Director |
| Elizabeth Williams President Vice President - Manufacturing Operations |
ImmuCell Management Team Effectiveness
The company has return on total asset (ROA) of 0.0302 % which means that it generated a profit of $0.0302 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0661 %, meaning that it created $0.0661 on every $100 dollars invested by stockholders. ImmuCell's management efficiency ratios could be used to measure how well ImmuCell manages its routine affairs as well as how well it operates its assets and liabilities.ImmuCell Workforce Comparison
ImmuCell is rated third overall in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 481. ImmuCell retains roughly 77.0 in number of employees claiming about 16% of equities under Health Care industry.
The company has Profit Margin (PM) of 0.06 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.09 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.09. ImmuCell Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ImmuCell insiders, such as employees or executives, is commonly permitted as long as it does not rely on ImmuCell's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, ImmuCell insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Te Boekhorst Paul Francis Olivier 16 hours ago Insider Trading | ||
Te Boekhorst Paul Francis Olivier a day ago Insider Trading | ||
Te Boekhorst Paul Francis Olivier 2 days ago Insider Trading | ||
Te Boekhorst Paul Francis Olivier 3 days ago Insider Trading | ||
Te Boekhorst Paul Francis Olivier few days ago Insider Trading | ||
Te Boekhorst Paul Francis Olivier six days ago Insider Trading | ||
Te Boekhorst Paul Francis Olivier over a week ago Insider Trading | ||
Te Boekhorst Paul Francis Olivier over a week ago Insider Trading |
ImmuCell Notable Stakeholders
An ImmuCell stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as ImmuCell often face trade-offs trying to please all of them. ImmuCell's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting ImmuCell's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael Brigham | CEO and President CFO, Treasurer, Secretary and Director | Profile | |
| P Boekhorst | CEO President | Profile | |
| Elizabeth Williams | Vice President - Manufacturing Operations | Profile | |
| Timothy Fiori | Secretary, CFO | Profile | |
| Elizabeth Toothaker | Director Administration | Profile | |
| John Zinckgraf | Director Development | Profile | |
| Bobbi Brockmann | VP of Sales and Marketing | Profile | |
| Gustavo Scaffa | Director Quality | Profile |
About ImmuCell Management Performance
The success or failure of an entity such as ImmuCell often depends on how effective the management is. ImmuCell management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of ImmuCell management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the ImmuCell management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Immucell operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 64 people.
Please note, the presentation of ImmuCell's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, ImmuCell's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of ImmuCell's management manipulating its earnings.
ImmuCell Workforce Analysis
Traditionally, organizations such as ImmuCell use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare ImmuCell within its industry.ImmuCell Manpower Efficiency
Return on ImmuCell Manpower
| Revenue Per Employee | 344.1K | |
| Revenue Per Executive | 3.3M | |
| Net Loss Per Employee | 28K | |
| Net Loss Per Executive | 269.6K | |
| Working Capital Per Employee | 138.1K | |
| Working Capital Per Executive | 1.3M |
Complementary Tools for ImmuCell Stock analysis
When running ImmuCell's price analysis, check to measure ImmuCell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ImmuCell is operating at the current time. Most of ImmuCell's value examination focuses on studying past and present price action to predict the probability of ImmuCell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ImmuCell's price. Additionally, you may evaluate how the addition of ImmuCell to your portfolios can decrease your overall portfolio volatility.
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume |